Shopping Cart
- Remove All
- Your shopping cart is currently empty
T-900607 is a novel microtubule protein active agent that disrupts microtubule polymerization through a unique mechanism of action. t-900607 is cardiotoxic.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $195 | In Stock | |
5 mg | $430 | In Stock | |
10 mg | $636 | In Stock | |
25 mg | $987 | In Stock | |
50 mg | $1,360 | In Stock | |
100 mg | $1,830 | In Stock | |
500 mg | $3,680 | In Stock |
Description | T-900607 is a novel microtubule protein active agent that disrupts microtubule polymerization through a unique mechanism of action. t-900607 is cardiotoxic. |
Targets&IC50 | MCF-7/ADR cells:< 5 μM, HeLa cells:< 5 μM |
In vitro | t-900607 (compound 5 or VI) showed total growth inhibition for HeLa and MCF-7/ADR cells at<5 μM.[2] |
In vivo | t-900607 (15 to 270 mg/m; administered intravenously; advanced and/or metastatic solid malignancies patients; over 30 minutes every 21 days) no DLTs were seen until 270 mg/m, the sixth dose level. The dose was decreased to 180 mg/m with increased cardiac monitoring and at this dose 3/4 of patients experienced cardiac toxicity. The study was reopened at 130 mg/m of 6 enrolled patients, 1 had grade 3 drug-related lethargy considered to be a DLT and this dose was considered the RP2D. No objective responses were seen but stable disease was reported on 7/20. The recommended phase II dose for t-900607 is 130 mg/m given as an intravenous infusion over 60 minutes on a 21-day cycle. Cardiac toxicity was seen with this schedule.[1] |
Molecular Weight | 411.3 |
Formula | C14H10F5N3O4S |
Cas No. | 261944-52-9 |
Storage | Shipping with blue ice. | ||||||||||||||||||||
Solubility Information | DMSO: 4.11 mg/mL (10 mM), Sonication is recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.